机构:[1]Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China[2]Guangdong Med Coll, Peoples Hosp Shenzhen 4, Dept Rheumatol, Shenzhen, Peoples R China[3]Capital Med Univ, Beijing Children Hosp, Dept Rheumatol, Beijing, Peoples R China首都医科大学附属北京儿童医院[4]Bengbu Med Coll, Affiliated Hosp, Dept Rheumatol, Bengbu, Peoples R China[5]Anhui Prov Hosp, Affiliated Hosp USTC 1, Dept Rheumatol, Hefei, Peoples R China[6]Peoples Hosp Xinjiang Autonomous Reg, Dept Rheumatol, Urumqi, Peoples R China[7]Zhengzhou Univ, Affiliated Hosp 1, Dept Rheumatol, Zhengzhou, Peoples R China[8]Cent South Univ, Xiangya Hosp, Dept Rheumatol, Changsha, Peoples R China[9]Airforce Mil Med Univ, Xijing Hosp, PLA Specialized Res Inst Rheumatol & Immunol, Dept Clin Immunol, Xian, Peoples R China[10]Capital Med Univ, Beijing Tongren Hosp, Dept Rheumatol, Beijing, Peoples R China临床科室风湿免疫科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[11]Natl Hlth Commiss PRC, China Japan Friendship Hosp, Dept Rheumatol, Beijing, Peoples R China[12]Nanjing Med Univ, Affiliated Hosp 1, Dept Rheumatol, Nanjing, Peoples R China江苏省人民医院[13]Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Rheumatol, Shantou, Peoples R China[14]Jilin Univ, Sino Japanese Friendship Hosp, Dept Rheumatol, Changchun, Peoples R China吉林大学中日联谊医院[15]China Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, Dept Epidemiol & Biostat, Beijing, Peoples R China
Objective: To study the long-term outcomes, in the context of both mortality and organ damage in patients with systemic lupus erythematosus (SLE) in the Chinese SLE Treatment and Research group (CSTAR) registry cohort. Methods: Patients were enrolled from April 2009 to February 2010 and they were followed up. The demographic data, clinical manifestations, labs test results and imaging examinations, disease activity (SLEDAI-2K), damage scores (SLLIC/Damage Index [SDI]), and medications were collected. Data were censored at either the last clinic visit or telephonic interview. Survival rate was analyzed by Kaplan-Meier (KM) method. COX proportional hazard model was adopted to perform the analysis of predicting factors for mortality and organ damage. Logistic regression analysis was employed to discuss the relationship among mortality, organ damage, and flare. Results: A total of 2104 patients were recruited at baseline and 1494 patients were followed up. The cumulative 1-year, 3-year, and 5-year survival rates were 98.3%, 96.9%, and 95.7%, respectively. Seventy-eight patients died during follow-up, and the main causes of death were infection (34.6%), active disease (26.9%), cardiovascular and cerebrovascular events (5.13%), and malignancy (5.13%). At entry, 247 patients presented with irreversible organ damage and it increased to 398 patients at the endpoint. The major accumulated organ damages were kidney (25.9%), musculoskeletal disease (20.2%), neuropsychiatric disease (12.2%), and pulmonary damage (10.9%). Cox regression analysis further showed that male, late disease onset, delayed diagnosis (diagnosis from disease onset >1 year), baseline organ damage, and specific organ involvements predicted for higher mortality. In addition, early disease onset was a protecting factor for organ damage, and anti-SSA was an independent predicting factor for new organ damage. Logistic regression analysis showed that flare predicted for more organ damage. Conclusion: The 5-year survival rate of Chinese SLE patients has improved and is comparable to Caucasians SLE patients. Disease flare impact on prognosis is the increasing risk of damage development. Early diagnosis, prevention for flare and damage to maintain remission, may improve outcome.
基金:
Chinese National Key Research RD Program [2017YFC0907601, 2017YFC0907602, 2017YFC0907603]; Chinese National High Technology Research and Development Program, Ministry of Science and Technology [2012AA02A513]; Chinese National Key Technology R&D Program, Ministry of Science and Technology [2008BAI59B02]
语种:
外文
被引次数:
WOS:
PubmedID:
第一作者:
第一作者机构:[1]Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China[*1]Peking Union Med Coll Hosp, Dept Rheumatol, 1 Shuaifuyuan,Wangfujing Ave, Beijing 100730, Peoples R China
推荐引用方式(GB/T 7714):
Wang Ziqian,Li Mengtao,Ye Zhizhong,et al.Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry[J].RHEUMATOLOGY AND IMMUNOLOGY RESEARCH.2021,2(3):195-202.doi:10.2478/rir-2021-0025.
APA:
Wang, Ziqian,Li, Mengtao,Ye, Zhizhong,Li, Caifeng,Li, Zhijun...&Zeng, Xiaofeng.(2021).Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry.RHEUMATOLOGY AND IMMUNOLOGY RESEARCH,2,(3)
MLA:
Wang, Ziqian,et al."Long-term outcomes of patients with systemic lupus erythematosus: A Multicenter Cohort Study from CSTAR registry".RHEUMATOLOGY AND IMMUNOLOGY RESEARCH 2..3(2021):195-202